Antiaging Quantu Financials
This page shows Antiaging Quantu (AAQL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scaled abruptly, but the company still depends on external financing because overhead and cash burn outrun gross profit.
After revenue scaled to$818K in FY2025, gross profit was only$429K , so the business still lacked enough contribution to fund its own overhead. Operating cash flow of-$900K ran below the-$720K net loss, a clue that working-capital and cash operating demands intensified as the company expanded.
The shift from FY2024 to FY2025 looks like a different revenue mix, not just more volume: gross margin fell from
Liquidity improved, with the current ratio moving from 0.3x to 1.2x, so near-term obligations were easier to cover by FY2025. But solvency weakened as liabilities reached
Financial Health Signals
We are recalculating Antiaging Quantu's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Antiaging Quantu scores 2.08, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($20.9M) relative to total liabilities ($2.4M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Antiaging Quantu passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Antiaging Quantu generates $0.20 in operating cash flow (-$171K OCF vs -$838K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Antiaging Quantu generated $1.0M in revenue in fiscal year 2026. This represents an increase of 26.5% from the prior year.
Antiaging Quantu's EBITDA was -$701K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.5% from the prior year.
Antiaging Quantu reported -$838K in net income in fiscal year 2026. This represents a decrease of 16.3% from the prior year.
Antiaging Quantu earned $-0.03 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 10.8% from the prior year.
Cash & Balance Sheet
Antiaging Quantu held $503K in cash against $0 in long-term debt as of fiscal year 2026.
Antiaging Quantu had 34M shares outstanding in fiscal year 2026. This represents an increase of 14.3% from the prior year.
Margins & Returns
Antiaging Quantu's gross margin was 67.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 15.5 percentage points from the prior year.
Antiaging Quantu's operating margin was -80.8% in fiscal year 2026, reflecting core business profitability. This is up 15.8 percentage points from the prior year.
Antiaging Quantu's net profit margin was -81.0% in fiscal year 2026, showing the share of revenue converted to profit. This is up 7.1 percentage points from the prior year.
Capital Allocation
AAQL Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12K-96.3% | $340K-12.8% | $390K+33.9% | $291K+1.1% | $288K+86.6% | $154K-10.8% | $173K-14.3% | $202K |
| Cost of Revenue | $73K-46.1% | $136K+107.6% | $66K+15.8% | $57K-84.7% | $370K+7064.4% | $5K-64.1% | $14K+8610.9% | $165 |
| Gross Profit | -$61K-129.9% | $204K-37.2% | $324K+38.2% | $235K+388.0% | -$81K-154.6% | $149K-6.0% | $159K-21.3% | $202K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $270K-32.5% | $401K+16.2% | $345K-4.2% | $360K+53.2% | $235K-17.2% | $284K+10.8% | $256K-10.0% | $285K |
| Operating Income | -$374K-37.3% | -$272K-431.5% | -$51K+62.9% | -$138K+23.0% | -$179K+9.7% | -$199K-0.5% | -$198K+7.6% | -$214K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $160+190.9% | $55-99.5% | $10K+74.1% | $6K | N/A | N/A | N/A | N/A |
| Net Income | -$371K-36.1% | -$272K-341.8% | -$62K+53.8% | -$133K+25.7% | -$180K-39.1% | -$129K+34.7% | -$198K+7.6% | -$214K |
| EPS (Diluted) | N/A | $-0.01-309.5% | $-0.00+53.3% | $-0.00 | N/A | $-0.00+34.8% | $-0.01+7.0% | $-0.01 |
AAQL Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.7M-4.8% | $1.8M-4.9% | $1.9M+13.8% | $1.7M+5.2% | $1.6M+0.8% | $1.6M+97.7% | $797K-24.1% | $1.1M |
| Current Assets | $1.2M-4.3% | $1.3M+3.8% | $1.2M+19.8% | $1.0M+25.9% | $811K+22.9% | $660K+291.0% | $169K-49.3% | $333K |
| Cash & Equivalents | $503K-46.3% | $937K+105.7% | $455K+12.3% | $406K+9.5% | $371K+83.0% | $202K+441.4% | $37K-69.5% | $123K |
| Inventory | $219K+115.0% | $102K+41.0% | $72K | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $30K | N/A | $468K+69.3% | $276K+222.0% | $86K+255.0% | $24K-17.6% | $29K-72.1% | $105K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.4M+13.6% | $2.1M-34.8% | $3.2M+10.0% | $2.9M+8.3% | $2.7M+331.0% | $631K-61.5% | $1.6M-2.2% | $1.7M |
| Current Liabilities | $1.7M+21.1% | $1.4M+15.3% | $1.2M+31.8% | $910K+34.2% | $678K+85.3% | $366K-68.3% | $1.2M+5.0% | $1.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$676K-124.8% | -$301K+77.5% | -$1.3M-5.1% | -$1.3M-12.5% | -$1.1M-219.5% | $946K+212.3% | -$842K-34.7% | -$625K |
| Retained Earnings | -$2.2M-19.7% | -$1.9M-17.0% | -$1.6M-4.0% | -$1.5M-9.5% | -$1.4M-14.6% | -$1.2M-11.7% | -$1.1M-21.9% | -$903K |
AAQL Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$426K-222.9% | $346K+272.7% | $93K+150.3% | -$185K+44.5% | -$333K+3.3% | -$344K-3576.3% | -$9K+95.6% | -$214K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$17-100.6% | $3K+101.8% | -$164K-14982.8% | -$1K+94.1% | -$19K-123300.0% | -$15+99.9% | -$15K+48.8% | -$30K |
| Financing Cash Flow | $0-100.0% | $120K0.0% | $120K-45.5% | $220K-57.6% | $519K+1.6% | $511K+936.1% | -$61K-130.6% | $200K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AAQL Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -488.3%-548.2pp | 59.9%-23.2pp | 83.2%+2.6pp | 80.5%+108.8pp | -28.3%-124.9pp | 96.7%+5.0pp | 91.7%-8.2pp | 99.9% |
| Operating Margin | -2992.1%-2912.1pp | -80.0%-66.9pp | -13.1%+34.3pp | -47.4%+14.9pp | -62.3%+66.4pp | -128.7%-14.5pp | -114.2%-8.3pp | -105.9% |
| Net Margin | -2966.2%-2886.2pp | -80.0%-64.2pp | -15.8%+30.0pp | -45.8%+16.6pp | -62.3%+21.3pp | -83.6%+30.6pp | -114.2%-8.3pp | -105.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -13.7% | N/A | N/A |
| Return on Assets | -21.5%-6.5pp | -15.0%-11.8pp | -3.2%+4.7pp | -8.0%+3.3pp | -11.3%-3.1pp | -8.2%+16.6pp | -24.8%-4.4pp | -20.4% |
| Current Ratio | 0.73-0.2 | 0.92-0.1 | 1.02-0.1 | 1.12-0.1 | 1.20-0.6 | 1.80+1.7 | 0.15-0.2 | 0.30 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 0.67 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$676K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.73), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is Antiaging Quantu's annual revenue?
Antiaging Quantu (AAQL) reported $1.0M in total revenue for fiscal year 2026. This represents a 26.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Antiaging Quantu's revenue growing?
Antiaging Quantu (AAQL) revenue grew by 26.5% year-over-year, from $818K to $1.0M in fiscal year 2026.
Is Antiaging Quantu profitable?
No, Antiaging Quantu (AAQL) reported a net income of -$838K in fiscal year 2026, with a net profit margin of -81.0%.
What is Antiaging Quantu's EBITDA?
Antiaging Quantu (AAQL) had EBITDA of -$701K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Antiaging Quantu's gross margin?
Antiaging Quantu (AAQL) had a gross margin of 67.9% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Antiaging Quantu's operating margin?
Antiaging Quantu (AAQL) had an operating margin of -80.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Antiaging Quantu's net profit margin?
Antiaging Quantu (AAQL) had a net profit margin of -81.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Antiaging Quantu's operating cash flow?
Antiaging Quantu (AAQL) generated -$171K in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Antiaging Quantu's total assets?
Antiaging Quantu (AAQL) had $1.7M in total assets as of fiscal year 2026, including both current and long-term assets.
What is Antiaging Quantu's current ratio?
Antiaging Quantu (AAQL) had a current ratio of 0.73 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
What is Antiaging Quantu's return on assets (ROA)?
Antiaging Quantu (AAQL) had a return on assets of -48.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Antiaging Quantu's cash runway?
Based on fiscal year 2026 data, Antiaging Quantu (AAQL) had $503K in cash against an annual operating cash burn of $171K. This gives an estimated cash runway of approximately 35 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Antiaging Quantu's debt-to-equity ratio negative or not reported?
Antiaging Quantu (AAQL) has negative shareholder equity of -$676K as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Antiaging Quantu's Altman Z-Score?
Antiaging Quantu (AAQL) has an Altman Z-Score of 2.08, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Antiaging Quantu's Piotroski F-Score?
Antiaging Quantu (AAQL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Antiaging Quantu's earnings high quality?
Antiaging Quantu (AAQL) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.